Can acotinib be purchased in domestic hospitals?

Acalabrutinib (Acalabrutinib) is a targeted therapy drug, mainly used to treat specific types of leukemia and lymphoma, such as chronic lymphocytic leukemia (CLL), small cell lymphoma (SLL span>), follicular lymphoma (FL) and diffuse largeB cell lymphoma (DLBCL), etc.

Acotinib is now on the market in China and has been added to the medical insurance list. Domestic patients can purchase it. But the price of medicine is quite high, about 50,000 yuan. For specific price information and medical insurance reimbursement ratios, patients are advised to consult their local hospital pharmacy for accurate information. Compared with domestic ones, the price of foreign generic acotinib drugs is more affordable. Especially for generic drugs produced in Laos and Bangladesh, the price of the Lao version is about more than 3,000 yuan, while the price of the Bangladeshi version is about 6,000 yuan. The price of these generic drugs is much lower than that of the domestic brand-name drugs, but their pharmaceutical ingredients are basically the same as the brand-name drugs.

Acotinib is a BTK inhibitor. Its mechanism of action is to interfere with the growth and proliferation of leukemia and lymphoma cells by selectively inhibiting BTK in the B cell receptor signaling pathway. BTK is a key protein in the B cell receptor signaling pathway and plays an important role in the growth, proliferation and survival of B cells. Therefore, by inhibiting the activity of BTK, acotinib can effectively inhibit the proliferation of abnormal B cells, thereby achieving the purpose of treating leukemia and lymphoma.

Acotinib treatment is usually personalized, and doctors will develop a treatment plan based on factors such as the patient's condition, pathological type, stage, and health status. When choosing acotinib as a treatment option, doctors typically perform genetic testing and molecular biology analysis to determine whether the patient has a specific genetic mutation or abnormality that would be amenable to treatment with the drug.

In conclusion, acotinib is an effective targeted therapy for patients with specific types of leukemia and lymphoma. Patients should consult their doctors for detailed evaluation and guidance on whether they are suitable for acotinib treatment and how to choose the best treatment option.